How JNJ (Johnson & Johnson) Makes Money in 2025: A Deep-Dive With Income Statement

Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io

Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.

Understanding how a healthcare conglomerate like JNJ (Johnson & Johnson) makes money is essential for investors and anyone interested in the business of pharmaceuticals, medical devices, and healthcare innovation. In this post, we break down JNJ's quarterly income statement (Q3 2025) using a Sankey chart to visualize the financial flows — what comes in, where it goes, and what's left as profit.

Quick JNJ Overview

Johnson & Johnson (JNJ) operates as a global healthcare leader, developing and marketing pharmaceuticals (Innovative Medicine), medical devices (MedTech), and formerly consumer health products. Revenue comes primarily from prescription drugs and advanced medical technologies, serving hospitals, clinics, and patients worldwide. The business is organized into two main segments: Innovative Medicine and MedTech, following the spin-off of its consumer health division.

Revenue Breakdown

• Total Revenue (Q3 2025): $24.0B (+6.8% YoY)
  • Innovative Medicine: $15.6B (64.9% of total, +6.7% YoY)
  • MedTech: $8.43B (35.1% of total, +6.8% YoY)
  • Growth is powered by strong pharmaceutical sales, new product launches, and steady demand for surgical and interventional medical devices.

Gross Profit and Margins

• Gross Profit: $16.7B (69.6% gross margin)
  • Cost of Revenue: $7.30B (+4.9% YoY)
  • JNJ maintains robust margins due to its high-value pharmaceutical portfolio and operational scale in MedTech.
• Most costs come from manufacturing, supply chain, and procurement of raw materials for drugs and devices.

Operating Income and Expenses

• Operating Income: $7.10B (+34.4% YoY, 29.6% margin)
• Operating Expenses: $9.59B (–6.2% YoY)
  • R&D: $3.67B (–25.8% YoY, 15.3% of revenue) — Focused on oncology, immunology, and next-generation medical devices.
  • SG&A: $5.92B (+12.2% YoY, 24.7% of revenue) — Includes global salesforce, marketing, and administrative functions.
  • JNJ continues to prioritize innovation in pharmaceuticals and devices while maintaining efficiency in its cost structure.

Net Income

• Pre-Tax Income: $7.49B (+124.5% YoY, 31.2% margin)
• Income Tax: $2.34B (31.2% effective tax rate)
• Net Income: $5.15B (+91.2% YoY, 21.5% net margin)
• JNJ converts a significant portion of sales into profit due to its scale, pricing power, and disciplined cost management.

What Drives JNJ's Money Machine?

• Innovative Medicine: 64.9% of revenue, driven by blockbuster drugs in oncology, immunology, and neuroscience.
• MedTech Expansion: MedTech delivered $8.43B, with growth in surgical robotics and cardiovascular devices.
• R&D Investment: $3.67B invested in pipeline drugs and device innovation, ensuring future growth.
• Future Growth Areas: Cell and gene therapies, digital surgery, and global expansion—these are strategic bets, not yet fully profitable.

Visualizing JNJ's Financial Flows

The Sankey chart below visualizes how each dollar flows from gross revenue, through costs and expenses, down to net income. This helps investors spot where value is created, what areas weigh on profits, and how efficiently the company operates.

• Most revenue flows into gross profit, with operating expenses (especially SG&A) taking the largest chunk.
• Even after large investments in R&D and global sales infrastructure, 21.5% of revenue drops to the bottom line.

Key Takeaways

• JNJ's money comes overwhelmingly from pharmaceuticals (Innovative Medicine) and MedTech.
• High gross and net margins illustrate the power of JNJ's diversified, innovation-driven business model.
• Heavy investment in R&D, balanced by efficiency in operating costs.
• Ongoing growth is driven by blockbuster drugs, MedTech innovation, and global expansion.

Explore More Investment Opportunities

For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:

📌 50 Undervalued Stocks (Best) overall value plays for 2025
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)

🔍 Check out these stocks on the Value Sense platform for free!

FAQ About JNJ's Income Statement

1. What is the main source of JNJ's revenue in 2025?

JNJ generates over 64.9% of its revenue from Innovative Medicine (pharmaceuticals), with the remainder from MedTech devices. The consumer health segment is no longer a contributor post-spin-off.

2. How profitable is JNJ in Q3 2025?

JNJ reported net income of $5.15B in Q3 2025, with a net margin of approximately 21.5%, reflecting strong profitability driven by high-margin pharmaceuticals and disciplined cost management.

3. What are the largest expense categories for JNJ?

The biggest expenses on JNJ's income statement are operating expenses, particularly Research & Development (R&D) at $3.67B and Sales, General & Administrative (SG&A) at $5.92B in Q3 2025. R&D investment focuses on pipeline drugs and device innovation.

4. Why does MedTech operate at a lower margin?

MedTech, despite generating $8.43B in revenue, operates at a lower margin due to ongoing investments in product development, regulatory compliance, and global sales expansion. JNJ believes these investments will drive long-term growth—even if the division is less profitable today.

5. How does JNJ's effective tax rate compare to previous years?

JNJ's effective tax rate in Q3 2025 was 31.2%, consistent with prior years. This moderate rate is primarily due to the geographic mix of earnings and ongoing tax optimization strategies.